Vertex (Buenos Aires, Argentina)
July 10, 2024
Mariana Zarankin, María S Pellegrini, Francisco Zenteno
2 citations
A 19-year-old patient with major depressive syndrome achieved complete symptomatic remission after a 7-month program of self-administered psilocybin microdoses, supported by weekly evaluations, clinical anamnesis, laboratory tests, and the Hamilton depression scale. Conventional pharmacological treatment was suspended without discontinuation symptoms, and improvements in communication, social interaction, and general well-being were observed. The authors suggest that psilocybin microdose treatments are promising tools for depression but note that scientific studies are needed to certify these findings.
Vertex (Buenos Aires, Argentina)
July 10, 2025
Micaela Dines, Adriana Bulacia, Paloma Bamondez et al.
Intravenous ketamine at subanesthetic doses offers rapid relief for depressive and suicidal symptoms in treatment-resistant major depression. A protocol for administering ketamine infusions in a general hospital, based on international guidelines, specifies inclusion and exclusion criteria, dosage, administration procedures, and patient monitoring. The protocol also addresses adverse effects and safety considerations, aiming to optimize ketamine's efficacy and safety for treatment-resistant depression.
Vertex (Buenos Aires, Argentina)
July 10, 2023
Tamara Chernoff, Bruno Kliger, Dante Hernán Venturini
Classic psychedelics like LSD, psilocybin, and DMT are psychoactive compounds that work mainly by activating serotonergic receptors. In appropriate doses, they produce profound changes in subjective experience, leading to altered states of consciousness that can include mystical, transcendental, or ego-dissolution phenomena. These experiences are linked to therapeutic effects in various mental health conditions. Psychedelics are considered safe, with low risk of serious adverse effects and no addictive potential. Current evidence comes from systematic reviews and meta-analyses of phase II clinical trials with small samples, strict exclusion criteria, and challenges with double-blind methods. This bibliographic review examines the phenomenological features of psychedelic experiences, their potential therapeutic uses, and underlying mechanisms.
Vertex (Buenos Aires, Argentina)
July 10, 2026
Marco Fierro, Abel Guerrero, Juan Toro
This narrative review describes the concept of the basic or minimal self and its alterations in schizophrenia spectrum disorders and the prodrome. The basic self is an implicit, pre-reflective sense of self-presence that grounds all experience from a first-person perspective. Anomalous self-experiences, where this first-person perspective is distorted, are considered core features of schizophrenia. The review highlights that publications on these topics are scarce in Spanish-language psychiatry.